Day One Biopharmaceuticals (NASDAQ:DAWN) Trading Up 3.8%

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) shares rose 3.8% during trading on Tuesday . The company traded as high as $14.44 and last traded at $14.38. Approximately 233,012 shares traded hands during mid-day trading, a decline of 62% from the average daily volume of 608,511 shares. The stock had previously closed at $13.85.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on DAWN. The Goldman Sachs Group cut their target price on Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating for the company in a research report on Tuesday, February 27th. Oppenheimer reiterated a “market perform” rating on shares of Day One Biopharmaceuticals in a research report on Tuesday, February 27th. Finally, Piper Sandler reiterated an “overweight” rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a research report on Tuesday, March 26th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $40.60.

Day One Biopharmaceuticals Stock Performance

The business has a 50 day moving average of $15.23 and a 200 day moving average of $13.67.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its quarterly earnings data on Monday, February 26th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.07). On average, equities analysts anticipate that Day One Biopharmaceuticals, Inc. will post -2.66 EPS for the current year.

Insider Activity

In other news, CFO Charles N. York II sold 2,666 shares of Day One Biopharmaceuticals stock in a transaction on Friday, February 16th. The stock was sold at an average price of $15.25, for a total value of $40,656.50. Following the transaction, the chief financial officer now directly owns 277,754 shares in the company, valued at approximately $4,235,748.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CFO Charles N. York II sold 2,666 shares of Day One Biopharmaceuticals stock in a transaction on Friday, February 16th. The stock was sold at an average price of $15.25, for a total value of $40,656.50. Following the transaction, the chief financial officer now directly owns 277,754 shares in the company, valued at approximately $4,235,748.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Samuel C. Blackman sold 2,258 shares of Day One Biopharmaceuticals stock in a transaction on Friday, February 16th. The shares were sold at an average price of $15.25, for a total value of $34,434.50. Following the completion of the transaction, the insider now owns 1,244,662 shares in the company, valued at $18,981,095.50. The disclosure for this sale can be found here. In the last three months, insiders have sold 45,781 shares of company stock worth $722,960. 8.40% of the stock is currently owned by company insiders.

Institutional Trading of Day One Biopharmaceuticals

Institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. boosted its position in shares of Day One Biopharmaceuticals by 8.1% in the 3rd quarter. Vanguard Group Inc. now owns 4,629,754 shares of the company’s stock worth $56,807,000 after purchasing an additional 346,090 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Day One Biopharmaceuticals by 38.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 447,138 shares of the company’s stock worth $5,486,000 after purchasing an additional 125,050 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Day One Biopharmaceuticals by 22.4% in the 3rd quarter. Bank of New York Mellon Corp now owns 220,296 shares of the company’s stock worth $2,703,000 after purchasing an additional 40,387 shares in the last quarter. Deutsche Bank AG boosted its position in shares of Day One Biopharmaceuticals by 5.5% in the 3rd quarter. Deutsche Bank AG now owns 177,137 shares of the company’s stock worth $2,173,000 after purchasing an additional 9,219 shares in the last quarter. Finally, TimesSquare Capital Management LLC boosted its position in shares of Day One Biopharmaceuticals by 41.8% in the 3rd quarter. TimesSquare Capital Management LLC now owns 1,142,610 shares of the company’s stock worth $14,020,000 after purchasing an additional 336,910 shares in the last quarter. Institutional investors and hedge funds own 87.95% of the company’s stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.